Lyrica

Central & peripheral neuropathic pain in adults including diabetic peripheral neuropathy & post-herpetic neuralgia. Generalized anxiety disorder (GAD) in adults. Adjunctive therapy in adults w/ partial seizures w/ or w/o secondary generalization. Management of fibromyalgia.

Neuropathic pain Initially 150 mg daily, may be increased to 300 mg daily after 3-7 days interval. Max: 600 mg daily after an additional 7-day interval. Epilepsy Initially 150 mg daily, may be increased to 300 mg daily after 1 wk. Max: 600 mg daily after an additional wk. GAD Initially 150 mg daily, may be increased to 300 mg daily after 1 wk, then to 450 mg daily following an additional wk. Max: 600 mg daily after an additional wk. Fibromyalgia 300-450 mg daily in 2 divided doses; begin at 75 mg bid & may be increased to 150 mg bid w/in 1 wk or may be further increased to 225 mg bid. Max: 600 mg daily after an additional wk. Renal impairment CrCl ≥60 mL/min Initially 150 mg daily in 2 or 3 divided doses. Max: 600 mg daily, ≥30 to <60 mL/min Initially 75 mg daily in 2 or 3 divided doses. Max: 300 mg daily, ≥15 to <30 mL/min Initially 25-50 mg as single daily dose or in 2 divided doses. Max: 150 mg daily, <15 mL/min Initially 25 mg as single daily dose. Max: 75 mg daily. Supplementary dose following haemodialysis Initially 25 mg daily as single dose. Max: 100 mg daily.

May be taken with or without food.

Hypersensitivity.

Hypersensitivity reactions including angioedema. Discontinue treatment immediately if symptoms of angioedema eg, facial, perioral, or upper airway swelling occur. Patients w/ current or history of substance abuse; severe CHF. May cause hematologic disorder. Dizziness, somnolence; loss of consciousness, confusion & mental impairment; transient visual blurring & other changes in visual acuity; CHF. W/drawal symptoms eg, insomnia, headache, nausea, anxiety, hyperhidrosis & diarrhea after short- & long-term treatment. Renal failure. Gradually discontinue treatment over min of 1 wk. Carefully evaluate patients for history of drug abuse &/or psychiatric disorders. Observe signs & symptoms of misuse, abuse or dependence (eg, development of tolerance, dose escalation, drug-seeking behavior). Risk of CNS depression w/ opioids. Increased opioid-related death risk w/ concomitant opioid use. Adjust hypoglycemic medications in diabetic patients who gain wt while on treatment. Not to be taken by patients w/ galactose intolerance, Lapp-lactase deficiency or glucose-galactose malabsorption. May influence ability to drive or use machines. Liver & kidney disease. Women of childbearing potential must use effective contraception during treatment. Not to be used during pregnancy. Not recommended during lactation. Ped patients <12 yr. Not recommended in childn & adolescents 12-17 yr. Elderly >65 yr; increased accidental injury (fall) due to dizziness & somnolence.

Dizziness, somnolence. Nasopharyngitis; increased appetite; euphoric mood, confusion, irritability, depression, disorientation, insomnia, decreased libido; ataxia, abnormal coordination, tremor, dysarthria, amnesia, memory impairment, attention disturbance, paraesthesia, hypoesthesia, sedation, balance disorder, lethargy; blurred vision, diplopia; vertigo; vomiting, constipation, flatulence, abdominal distension, dry mouth; muscle cramp, arthralgia, back & limb pain, cervical spasm; peripheral oedema, oedema, abnormal gait, fall, drunk or abnormal feeling, fatigue; increased wt. Headache; nausea, diarrhea.

May potentiate effects of ethanol & lorazepam. Additive impairment of cognitive & gross motor function w/ oxycodone. Resp failure, coma & death w/ other CNS depressants. Reduced lower GIT function w/ medications having potential to produce constipation eg, opioid analgesics.

Anticonvulsants / Anxiolytics / Drugs for Neuropathic Pain

N02BF02 - pregabalin ; Belongs to the class of gabapentinoids. Used to relieve pain and other conditions.

D